Replies to post #135904 on Biotech Values

[ghmm]

MITI:

I don't follow the company closely but recall they merged with CancerVax a while ago. I am curious if the main value was from their pipeline or if anything of value came from CancerVax. TIA

[biomaven0]

I do think MITI had a chance to do well.

I agree, but things did seem to move very, very slowly for some reason. I've held the stock since mid-2010 ( http://www.siliconinvestor.com/readmsg.aspx?msgid=26614840 ) so I ended up doing fine, but I came close to selling it several times.

Whenever I grumble about a takeover I remember SCIOS - I grumbled mightily at the time when JNJ took them out, and look how that eventually turned out...

Overall though, I think I would have done way better had all the biotech stocks I've had acquired stayed in my portfolio. CNTO and LEVP are two in particular that I regret.

Peter

[DewDiligence]

…in the spirit of disclosure, a quarter of my position got called away at 10 last Saturday. So chalk up a partial point to those on the opposite side of the covered call debate:-)

Bravo! In the time I’ve been posting on iHub, I’ve seen literally hundreds of posts boasting about the “free money” to be had by selling covered calls, as though there were no downside to such an approach. Your post is one of the very few times—perhaps the only time—where I’ve seen someone acknowledge that selling calls ended up costing money.

p.s. For some reason, this subject generates heat and passion like few others. One regular poster ended up leaving this board permanently because he couldn’t stand the criticism levied against what he thought was a brilliant covered-call program.

[wallstarb]

So you sold at $10 last Saturday? That wasn't a huge opportunity cost as it's $10.90

[akasidney86]

PGS:
I'm exiting MITI also, and was curious if you or any of the other board pros (to all of whom I'm deeply indebted) has looked at PRAN and have any thoughts to share.
TIA